Teva Raises Guidance Amid Generics Growth
Firm Is Actively Examining BD Opportunities; Also Provides Update On Israel Conflict
Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.
You may also be interested in...
Teva has celebrated a US nod for its generic version of Forteo, the first substitutable teriparatide rival to be approved by the US Food and Drug Administration.
Sun delivered an exceptional Q2 performance, marred by a 9% decline in its US business due to a significant drop in lenalidomide sales.
Teva has announced that R. Ananthanarayanan – known as Ananth – is to rejoin the company as CEO of its active pharmaceutical ingredients business after taking leading roles at Cipla and Strides in recent years. Meanwhile, Strides has disclosed a change of chief operating officer coming next year, while Civica Rx has named a manager for its sterile injectables operations.